登上Cell子刊：迈威生物ADC新药，有望克服多重耐药胃肠道癌症

Core Viewpoint - Gastrointestinal (GI) cancers, including liver, stomach, pancreatic, neuroendocrine tumors, and colorectal cancer, are major causes of cancer-related deaths globally, accounting for approximately 24.6% of all cancer diagnoses and 34.2% of cancer deaths [2] Group 1: Cancer Statistics and Challenges - Colorectal cancer (CRC) ranks third in incidence and second in mortality among all cancers globally, while pancreatic cancer, despite its lower incidence, has the highest mortality rate [2] - Effective screening strategies are primarily limited to CRC, stomach, and esophageal cancers, leading to late-stage diagnoses in many cases, often with no possibility of cure [2] - Nearly 50% of patients diagnosed at an early stage may experience disease recurrence, resulting in poor overall prognosis [2] Group 2: Treatment Challenges and Innovations - Surgical interventions and postoperative chemotherapy have reduced mortality rates, but adverse reactions and drug resistance remain significant challenges [2] - Immunotherapy has emerged as a promising treatment method, yet its efficacy is currently limited to a small subset of patients, highlighting the urgent need for better therapeutic targets and new treatments in GI cancers [2] Group 3: Research on 7MW4911 - A recent study published in Cell Reports Medicine demonstrated that the CDH17-targeted antibody-drug conjugate (ADC) 7MW4911, conjugated with the DNA topoisomerase inhibitor MF-6, showed promising therapeutic effects against multidrug-resistant GI tumors in mouse models [3][6] - CDH17 is highly expressed in GI cancers, with nearly 100% expression in colorectal cancer clinical samples and 23%-88% in other GI cancers, correlating with tumor progression and poor clinical outcomes [5] - Preclinical evaluations indicated that 7MW4911 exhibited strong tumor-killing activity and significant tumor growth inhibition in various GI cancer models, along with favorable pharmacokinetics and safety profiles in non-human primate studies [7][8][10]